Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of ACC-1898 (Tyrosine Kinase Inhibitor) in Adult Participants With Advanced Solid Tumors.

NCT07252661 is registered in ClinicalTrials.gov with AccSalus Biosciences, Inc. as lead sponsor.

NCT NCT07252661
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07252661 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of ACC-1898 (Tyrosine Kinase Inhibitor) in Adult Participants With Advanced Solid Tumors.
Lead sponsor
AccSalus Biosciences, Inc.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
January 31, 2026
Completion date
December 31, 2027
Enrollment
40 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, gall bladder cancer, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, hepatocellular carcinoma, melanoma, renal cell carcinoma, thyroid carcinoma primary differentiated, thyroid carcinoma, medullary